tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ascendis Pharma announces FDA approved SKYTROFA

Ascendis Pharma (ASND) announced that the U.S. Food & Drug Administration, FDA, has approved SKYTROFA for the replacement of endogenous growth hormone in adults with growth hormone deficiency, a rare disorder resulting from decreased or total loss of growth hormone production. Lonapegsomatropin is a prodrug of somatropin administered once weekly, providing sustained release of active, unmodified somatropin. The FDA’s approval of SKYTROFA for adult GHD was based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled and active-controlled clinical trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily somatropin in adults with GHD.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1